Translation towards personalized medicine in Multiple Sclerosis

Area of Science:

• Genomic Medicine
• Neuroimmunology
• Pharmacogenetics

Background:

• The traditional 'one-size-fits-all' approach to disease treatment is insufficient, necessitating a shift towards personalized medicine.
• Multiple Sclerosis (MS) is a chronic, progressive neurological disease where individualized treatment is critical to prevent irreversible dysfunction.
• Evidence suggests MS is not a single entity, with varying patient responses to therapies influenced by genetics, environment, and demographics.

Purpose of the Study:

• To highlight the imperative for personalized medicine in managing Multiple Sclerosis.
• To discuss the role of genomics and pharmacogenetics in tailoring MS treatments.
• To identify challenges and future prospects for implementing personalized medicine in MS clinical practice.

Main Methods:

• Review of recent advances in genome-wide gene expression profiling and pharmacogenetics studies in MS.
• Analysis of factors influencing disease subtypes, activity, and medication response, including genetics, environment, and demographics.
• Identification of limitations in current pharmacogenetics research, such as the lack of consensus on clinical response assessment.

Main Results:

• Genomic technologies are increasingly applied to MS research, advancing pharmacogenetics.
• Genetic and environmental factors significantly influence MS subtypes and individual treatment responses.
• Current pharmacogenetics data for MS is not yet mature enough for widespread clinical application.

Conclusions:

• Personalized medicine holds significant potential for optimizing Multiple Sclerosis treatment strategies.
• Overcoming methodological limitations in pharmacogenetics studies is essential for clinical translation.
• With technological advancements, personalized medicine for MS is anticipated in the near future.